O complexo distrofina-glicoproteínas associadas (DGC) localiza-se no sarcolema das células musculares esqueléticas e cardíacas e tem como função principal proporcionar ligação mecânica entre o citoesqueleto intracelular e a matriz extracelular. Estudos prévios realizados em nosso laboratório, focalizando o complexo DGC, demonstraram perda de proteínas importantes desse complexo. As situações avaliadas anteriormente foram: infecção experimental por Trypanosoma cruzi (T. cruzi) e sépsis experimental. Em ambas as situações verificou-se a perda da distrofina acompanhada por disfunção contrátil e aumento nos níveis da calpaína, protease dependente de cálcio implicada na proteólise da distrofina. Todavia, o mecanismo responsável pela ativação das calpaínas e proteólise da distrofina na infecção experimental por T. cruzi e na sépsis experimental não está totalmente definido. O objetivo desse trabalho foi avaliar in vitro o mecanismo responsável pela ativação das calpaínas nas culturas de cardiomiócitos desafiadas com o soro dos animais infectados experimentalmente com T. cruzi ou com o soro dos animais submetidos à sépsis grave experimental. Camundongos C57BL/6 foram submetidos à sépsis grave ou infectados com a cepa Y de T. cruzi. No pico de expressão das citocinas pró-inflamatórias, 12 dias após inoculação do parasito ou 6 horas após a indução da sépsis, o sangue foi coletado e o soro separado. Corações de camundongos recém-nascidos foram isolados para o cultivo dos cardiomiócitos. No quinto dia após o início das culturas, as células foram estimuladas com 10% do soro de animais infectados com T. cruzi ou o soro de animais submetidos à sépsis grave durante 24 horas. Após, as células foram coletadas para análises de Western blotting e imunofluorescência para verificar a expressão da distrofina e calpaína-1. Avaliou-se também, por imunofluorescência, a expressão do NF-B. Os cardiomiócitos foram estimulados e tratados com o dantrolene, inibidor da liberação de cálcio do retículo sarcoplasmático, ou ALLN, inibidor da calpaína-1, e após coletados para verificar a expressão da distrofina e calpaína-1 por Western blotting e imunofluorescência. Nossos resultados mostraram uma redução significativa na expressão da distrofina com desarranjo das miofibrilas contráteis e formação de bolhas citoplasmáticas, além de um aumento nos níveis da calpaína-1 e do NF-B. O tratamento com dantrolene nas culturas estimuladas com o soro de animais infectados experimentalmente com T. cruzi ou com o soro dos animais submetidos à sépsis grave, recuperou a expressão da distrofina e reduziu os níveis da calpaína-1. O tratamento com ALLN nos cardiomiócitos estimulados com o soro de animais infectados experimentalmente com T. cruzi recuperou a expressão da distrofina e não alterou os níveis da calpaína-1. Nas culturas estimuladas com o soro dos animais submetidos à sépsis grave, o tratamento com o ALLN recuperou a expressão da distrofina e reduziu os níveis da calpaína-1. Nossos resultados demonstraram que citocinas pró-inflamatórias presentes no soro dos animais infectados experimentalmente com T. cruzi como também no soro dos animais submetidos à sépsis grave induziriam um aumento no influxo de cálcio com consequente ativação das calpaínas, as quais atuariam na ativação do NF-B e na degradação da distrofina. Esse mecanismo poderia ser responsável pela proteólise da distrofina cardíaca observada na infecção experimental por Trypanosoma cruzi como também sépsis experimental. Mais estudos são necessários para elucidar este mecanismo, principalmente em relação a inibidores dos canais de cálcio, das citocinas pró-inflamatórias e das calpaínas, com o objetivo de fornecer novas vias de intervenção na prevenção de alterações cardíacas observadas na doença de Chagas e na sépsis. / The dystrophin-glycoprotein complex (DGC), located in the sarcolemma of cardiac and skeletal muscle cells and concentrated along the plasma membrane in costameric structures provides a framework that connects the intracellular cytoskeleton to the extracellular matrix. Previous studies from our laboratory clearly demonstrated disruption of DGC proteins in experimentally-induced T. cruzi infection and experimental sepsis. Both situation presented dystrophin disruption associated with contractile dysfunction and increased calpain levels, calcium dependent protease responsible for dystrophin proteolysis. However, the mechanism responsible for calpain activation and dystrophin proteolysis in experimentally-induced T. cruzi infection and experimental sepsis is not totally understood. The aim of this study was to evaluate in vitro the mechanism responsible for calpain activation in cultured cardiomyocytes challenged with serum from animals experimentally infected with T. cruzi or subjected to severe sepsis. Mice C57BL/6 were subjected to sepsis induction or infected with Y strain from T. cruzi. At the peak of proinflammatory cytokines expression, 12 days after parasite inoculation or 6 hours after sepsis induction, the blood was collected and the serum separated. Hearts from newborn mice were isolated for culture of cardiomyocytes. After 5 days of incubation, the cardiac cells were stimulated with 10% of serum from animals experimentally infected with T. cruzi or subjected to severe sepsis during 24 hours, and collected for Western blotting and immunofluorescence analysis to verify dystrophin and calpain-1 expression. The expression of NF-B was evaluated by immunofluorescence. The treatments with dantrolene, inhibitor of calcium release from sarcoplasmic reticulum, or ALLN, calpain-1 inhibitor, were performed in cultured cardiomyocytes stimulated during 24 hours with serum from animals infected with T. cruzi or subjected to severe sepsis, and dystrophin and calpain-1 expression were analyzed by Western blotting and immunofluorescence. Our results demonstrated loss of dystrophin associated with myofibers derangement and presence of cytoplasmic blebs as well increase of calpain-1 and NF-B expression. The dantrolene treatment in cultures stimulated with serum from animals infected with T. cruzi or subjected to severe sepsis recovey dystrophin expression and reduced calpain-1 levels. The ALLN treatment in cardiomyocytes stimulated with serum from animals infected with T. cruzi recovery dystrophin expression and preserved calpain-1 levels. In cultures stimulated with serum from animals subjected to severe sepsis, the ALLN treatment recovery dystrophin expression and decreased calpain-1 levels. Our results demonstrated that proinflammatory cytokines in serum from mice infected with T. cruzi or subjected to severe sepsis could induce an increase calcium influx with calpain activation, which could act in NF-B activation and dystrophin disruption. Possibly, this mechanism could be responsible to dystrophin proteolysis observed in experimentally-induced acute T. cruzi infection and experimental sepsis. More studies are needed to elucidate this mechanism, especially in relation to calcium channel blockers and inhibitors of pro-inflammatory cytokines and calpains, which may provide new routes for intervention to prevent cardiac damage in Chagas disease and sepsis.

La myopathie de Duchenne est une maladie génétique qui se caractérise principalement par une dégénérescence progressive des muscles squelettiques dont la cause est l’absence de dystrophine fonctionnelle dans les muscles. A ce jour, il n’existe toujours pas de traitement efficace contre ces maladies. Comme le plus grand gène connu chez l’Homme, la dystrophine code pour une protéine de 427kDa. La protéine connecte l’actine avec le DAPC (Dystrophin Associated Protein Complex) dans les muscles striés. Pour l’instant, il y a 3 hypothèses concernant le mécanisme du DMD. L’absence de la dystrophine peut supprimer le lien physique entre les protéines structurales de la membrane basale (laminines) et les protéines structurales du cytosquelette (filaments intermédiaires et actine), ou la distribution et la fonction des canaux ioniques, ou des voies de signalisation nécessaires à la survie du muscle. Caenorhabditis elegans ne possède qu’un homologue du gène de la dystrophine humaine, le gène dys-1. La protéine DYS-1 présente 37% d’homologie avec la dystrophine humaine. Le double mutant dys-1(cx18) ; hlh-1(cc561) présente une forte dégénérescence musculaire. Comme le sarcomère de C. elegans ressemble au sarcomère de mammifère, C. elegans est modèle pertinent d’étude la maladie. En vue de comprendre la raison du DMD chez les mammifères et chez les vers, le groupe L. SEGALAT a effectué des cribles pour identifier les molécules et les gènes qui peuvent supprimer la dégénérescence musculaire. On a trouvé un gène pkc-2 qui est capable de supprimer la dégénérescence musculaire chez C. elegans. La protéine PKC-2 est l’orthologue de la Protein Kinase C Alpha (PKC) humaine et appartient à la famille du serine/threonine protéine kinase. Afin d’étudier la fonction du gène pkc-2, on a analysé l’expression du gène avec les construits différents in vivo et a utilisé la technique de double-hybride dans la levure. De plus, le crible par EMS (éthane méthyle sulfonâtes) a identifié une molécule sérotonine (5-HT) qui est un neuromédiateur, et supprime partiellement la dégénérescence musculaire des doubles mutants dys-1; hlh-1. La sérotonine a aussi un effet fort sur le mutant pkc-2(ok328), puisqu’elle provoque un phénotype blister. Ça nous permet de rechercher le lien entre la signalisation sérotoninergique et pkc-2. Le crible génétique peut contribuer à la connaissance du rôle pkc-2. […]. Elle sert aussi de plate-forme de voie de signalisation intracellulaire. L’identification de Y59A8A.3 propose la possibilité que pkc-2 modifie la filamin A par l’intermédiaire de la filamin A interacting protéine 1. Le crible génétique par EMS pour rechercher des suppresseurs de l’effet blister de la sérotonine sur les mutants pkc-2(ok328) a donné 8 candidats sur 5000 F1s : cx253, cx254, cx259, cx263, cx267, cx268, cx270, cx276. Les mutations ont été localisées sur les chromosomes par SNP mapping avec une souche de C. elegans très polymorphe, mais le temps a manqué pour leur identification exacte. L’expérience valide notre approche à étudier le lien entre la signalisation sérotoninergique et pkc-2. En résumé, le but de la thèse était de rechercher la fonction du gène pkc-2 dans les mécanismes moléculaires conduisant à la nécrose musculaire en absence de dystrophine. Les résultats présentés dans la thèse apportent des réponses aux questions fondamentales sur pkc-2 et aussi demandent des expériences supplémentaires afin de élucider plus avant les mécanismes de la dégénérescence musculaire dystrophine-dépendante. / Duchenne Muscular Dystrophy (DMD) is an X-linked progressive muscle disease which is caused by mutations in the dystrophin gene. Until now, there is no effective therapy for DMD. As the largest gene in human beings, it produces a 427-kDa cytoskeleton protein: Dystrophin. Dystrophin links actin and dystrophin associated protein complex (DAPC) in muscles. Currently, there are 3 hypotheses to explain the mechanisms of DMD. They suggest that the absence of dystrophin could lead to periodic muscle cell membrane ruptures, or affect the distribution and function of ion channels, or perturb signal transduction pathways. In Caenorhabditis elegans, there is only one homologue of mammalian dystrophin gene named dys-1, and the nematode protein DYS-1 presents 37% similar to the human one. The double mutant dys-1; hlh-1 exhibits a severe progressive muscle degeneration. The protein composition of the sarcomere has been studied and it has revealed a high degree of similarity with mammalian sarcomere. These allow C. elegans be a relevant animal model to study DMD.To understand why the lack of dystrophin induces muscle degeneration in mammals and worms, and to find new drugs that might help in reducing muscle degeneration, L. Ségalat and his coworkers performed several screens for drugs and genes suppressing muscle degeneration. An interesting gene pkc-2 came out and was considered as a possible regulator in the process of muscle degeneration in C. elegans. The protein that is encoded by this gene in C. elegans is an orthologous of the human gene Protein Kinase C Alpha (PKC), which belongs to the family of serine/threonine specific protein kinases. To study the function of pkc-2, we generated different recombinant constructs, analyzed the expression pattern of pkc-2 with immunocytochemistry, and performed yeast two-hybrid to search for PKC-2 binding partners. In addition, a neurotransmitter serotonin (5-HT) was found by drug screening to be an active blocker of striated muscle degeneration. As C. elegans lacking PKC-2 displays a severe blister phenotype in exogenous 5-HT, studying the correlation between PKC-2 and 5-HT therefore seems to be an opportunity to explore the reasons of muscle degeneration. A genetic screen with EMS (ethane methyl sulfonate) to search serotonin resistant mutant in strain pkc-2 (ok328) would help us study further about the role of pkc-2.In this thesis, different clones myo3::pkc-2 and pkc-2::gfp were made to inject into wild-type animals. The results revealed that pkc-2 expressed intensely in neurons and pharynx, but was not found in body-wall muscles. Mutants dys-1;hlh-1 fed with pkc-2 RNAi did not reduce muscle degeneration statistically comparing to triple mutant pkc-2;dys-1;hlh-1. This indicated that PKC-2 may be dominantly acting in neurons. A yeast two-hybrid screen identified the gene Y59A8A.3, which is a homologue to mammalian filamin A interacting protein 1 isoform 3, as a binding partner of PKC-2. Filamin A is a cytoskeleton protein, anchoring various trans-membrane proteins to the actin cytoskeleton and may also function as an important signaling scaffold. The result suggested that PKC-2 may therefore modulate filamin A activity through the filamin interacting protein 1. Genetic screen by EMS presented 8 candidates named cx253, cx254, cx259, cx263, cx267, cx268, cx270, cx276, which were mapped on chromosomes by SNP mapping using a polymorphic C. elegans strain, but time was too short to identify these genes formally. The experiment also offered possibilities of searching links between PKC-2 and serotonin pathways.In summary, this work studied the gene pkc-2 in order to reveal the function of PKC-2 and its involvement in muscle degeneration. The present results answered some questions about pkc-2, and needed further researches to elucidate the in vivo role of PKC-2 protein and its interaction with other proteins in the mechanism of muscle dystrophy in C. elegans.

Les dystrpohies musculaires sont des maladies génétiques rares qui se caractérisent par une dégénérescence musculaire progressive. la Dystrophie Musculaire de Duchenne (DMD) qui est la plus sévère d'entre elles est due à des mutations dans le gène de la dystrophine. Les mécanismes cellulaires impliqués dans le processus de dégénérescence des muscles restent peu compris et aucun traitement efficace n'existe à ce jour. Notre équipe a développé un modèle de la DMD chez le nématode C. elegans qui présente une dégénérescence musculaire progressive. Pendant ma thèse, j'ai caractérisé le processus de dégénérescence musculaire chez ce modèle par microscopie électronique. J'ai également contribué à une étude du rôle des mitochondries dans la dégénérescence musculaire dystrophine-dépendante chez le nématode. Par ailleurs, j'ai étudié l'effet de suppresseurs pharmacologique et génétiques de la dégénérescence musculaire dystrophine-dépendante. Enfin, j'ai pu mettre en évidence que la force exercée par le muscle influence le taux de dégénérescence musculaire. L'ensemble des résultats obtenus au cours de ma thèse, suggèrent que la perte de fonctions de la dystrophine affecte chez le nématode l'intégrité du sarcolemme et des structures d'ancrage des sarcomères et déclenche ainsi une cascade d'événements intracellulaires conduisant in fin à la mort de la cellule musculaire. Ainsi mes travaux dethèse mettent en évidence de nouveau mécanismes cellulaires impliqués dans la dégénérescence musculaire et ouvrent de nouvelles perspectives pour le développement de thérapie visant à cibler les défauts primaires ou secondaires induits par la perte de fonction de la dystrophine / Muscle dystrophies are genetic diseases caraterized by progressive muscle degeneration. Duchenne Muscular Dystrophy (DMD) is the most severe and is due to a mutation in the gene coding the dystrophin protein. The cellular mechanisms implicated in the degenerating process arte not understood yet and there is still no efficient treatment to cure the disease. Our group decvelopped a DMD model in C. elegans that presents progressive muscle degeneration. During my PhD thesis, I characterized the process of muscle degeneration in this model by electron microscopy. I also contribued to an investigation of the role of mitochondira in dystophin-dependant muscle degeneration. I also studied the effect of pharmacological and genetic suppressors of muscle degeneration. Finally, I showed that the force developped by the worm to move influences the level of muscle degeneration. Altogether, the results I obtained during my PhD thesis, suggest that the loss of funciotnof the dystrophin protein affects the integrity of the muscle plasma membrane and the sarcomeres anchoring structures triggering a cascade of intracellular events leading to the muscle cell death in C. elegans. Therefore, my results highlight new cellular mechanisms implicated in the phenomenon of muscle degeneration and open new perspectives for the development of therapies targeting primary and secondary defects induced by the dystrophin loss of function.

Les techniques de criblage actuelles (in vitro et in silico) sont dépendantes des efforts menés en biologie médicinale pour identifier des cibles biologiques pertinentes ; cibles difficiles à définir pour les maladies génétiques dites "perte de fonction". De plus, les composés issus de ces cribles s'avèrent souvent inefficaces et/ou toxiques une fois confrontés à la complexité physiologique d'un organisme entier. Pour contourner ce problème, nous proposons d'utiliser le nématode C. elegans, notamment pour des maladies répondant aux critères suivants : i) physiopathologie complexe et/ou mal comprise excluant le développement à court terme de médicaments sur une base rationnelle, ii) peu d’espoir de thérapie génique/cellulaire à court terme, iii) conservation chez C. elegans du gène relié à la maladie humaine et induisant un phénotype exploitable une fois inactivé. Nous démontrons ici que ce petit nématode permet de tester, à moindre coût, un grand nombre de composés chimiques tout en conservant la complexité physiologique d'un animal entier. De plus, la souplesse génétique de cet animal permet d'apporter rapidement des informations sur le mode d'action des composés identifiés. Ainsi, en plus du but initial visant à identifier des molécules bioactives à intérêt thérapeutique, cette approche peut permettre de dégager de nouvelles cibles moléculaires utiles pour l'industrie chimique, et cruciales pour la recherche de traitements contre les maladies perte de fonction. Finalement, nous présentons comment mettre en place une telle stratégie, notamment pour la myopathie de Duchenne, l'amyotrophie spinale et le syndrome de Schwartz-Jampel. Enfin, nous présentons les résultats obtenus lors des différentes campagnes de criblage, les validations des molécules les plus prometteuses et les travaux effectués pour tenter de comprendre leur mode d'action chez le nématode. / Current high-throughput screening methods for drug discovery rely on the existence of targets. Moreover, most of the hits generated during screenings turn out to be invalid after further testing in animal models. To by-pass these limitations, efforts are now being made to screen chemical libraries on whole animals. One of the most commonly used animal model in biology is the murine model Mus musculus. However, its cost limits its use in large-scale therapeutic screening. In contrast, the nematode Caenorhabditis elegans is gaining momentum as screening chemical tool. This tiny worm combines genetic amenability, low cost, and culture conditions that are compatible with large-scale screens. Its main advantage is to allow high-throughput screening in a whole-animal context. Moreover, its use is not dependent on the prior identification of a target and permits the selection of compounds with an improved safety profile. Here, we introduce this approach with the Duchenne Muscular Dystrophy, the Spinal Muscular Dystrophy and the Schwartz-Jampel syndrome. We present the methodology used with each model to screen up to 7,000 compounds and the results of these screening campaigns. We further present the validation of our best hits and try to understand their mechanism of action.

No description available.